Clinical Trial of AVL-3288 in Schizophrenia Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients with schizophrenia.

Key facts

Study ID
NCT02978599
Run by
New York State Psychiatric Institute
People needed
24
Starts
2016-11-01
Expected to finish
2018-11-02
Last updated by the study team
2019-01-22

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.